Compare MRKR & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | BFRI |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 16.3M |
| IPO Year | 2010 | 2021 |
| Metric | MRKR | BFRI |
|---|---|---|
| Price | $0.95 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $7.87 | $6.00 |
| AVG Volume (30 Days) | 60.0K | ★ 631.5K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.61 | ★ 67.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,705,000.00 |
| Revenue This Year | $19.61 | $10.65 |
| Revenue Next Year | $375.85 | $15.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $0.84 | $0.57 |
| 52 Week High | $2.46 | $1.66 |
| Indicator | MRKR | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 30.31 |
| Support Level | N/A | $0.78 |
| Resistance Level | $1.31 | $0.98 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 5.58 | 10.98 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.